Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dexpanthenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Dexpanthenol (Sinecort, BAY81-2996) | DRUG | 1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter) |
| Positive control, Na-laurylsulfat-solution | DRUG | 50 mikro liter of 0.5 % Sodium-laurylsulfate-solution |
| Untreated skin under application chamber | DEVICE | Application of treatment chamber as in arm 1 and arm 2 on untreated skin |
Inclusion Criteria: * Age of at least 18 years * Skin type I, II, or III according to Fitzpatrick * Subjects of childbearing potential must use an acceptable method of contraception. Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are considered acceptable methods o...
Dexpanthenol is a small molecule drug being developed by Bayer AG under the code BAY81-2996. It is also known by the name Sinecort. It has been studied in a Phase 1 clinical trial, and the specific therapeutic indication has not been disclosed.
Dexpanthenol is developed by Bayer AG, which trades under the ticker BAYRY. The drug is also referred to as Sinecort or by the development code BAY81-2996.
Dexpanthenol is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are currently no active trials. It is an investigational drug and has not been approved by the FDA.
Dexpanthenol has been evaluated in one completed Phase 1 trial, NCT00885937, titled a comparative safety study of a new Sinecort formulation versus positive control. The trial enrolled 33 healthy adult volunteers in Germany and was randomized and placebo-controlled.
Yes, Dexpanthenol is also known as Sinecort and by the development code BAY81-2996. These names refer to the same small molecule drug developed by Bayer AG.